zinc finger protein 26Genealiases: HEL-179 · KOX20
Q-omics provides the consensus-scored ZNF26 profile across patient tissues and cancer cell-line models. ZNF26 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF26 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF26 RNA expression shows 21,089 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where ZNF26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF26 survival associations across molecular data types. ZNF26 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF26 RNA expression–survival associations across cancer types. High ZNF26 expression shows unfavorable associations in KIRC, KICH, MESO, LIHC and ACC, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF26 RNA expression.
This table summarizes ZNF26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF26 shows higher tumor expression in HNSC, KIRC, BLCA, KIRP, LIHC and COAD. The HNSC box plot shows higher ZNF26 RNA expression in tumor versus normal tissue (log2 FC = +0.585, t-test p < 0.001).
This table shows molecular features associated with ZNF26 in patient tissues and cancer cell lines. In patient samples, ZNF26 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
